Sahai J, Gallicano K, Ormsby E, Garber G, Cameron D W
University of Ottawa AIDS Research Group, Ottawa General Hospital, Ontario, Canada.
AIDS. 1994 Jun;8(6):793-6. doi: 10.1097/00002030-199406000-00011.
To determine whether there is a simple relationship between body weight or body surface area (BSA) and serum zidovudine pharmacokinetic parameters in patients receiving oral zidovudine.
Single-dose, pharmacokinetic study.
Fifty-three asymptomatic and symptomatic HIV-infected men (CD4+ cell count < 500 x 10(6)/l) participated in the study. Results of renal function and haematology tests were within normal limits and all hepatic function tests were up to three times the upper limit of normal. Patients received 200 mg oral zidovudine and serial blood samples were collected for 4 h (18 patients) or 8 h (35 patients). Serum zidovudine concentrations were measured by high-performance liquid chromatography (12 patients) or radioimmunoassay (41 patients). Pharmacokinetic parameters were calculated by non-compartmental methods. The relationships between body weight or BSA and maximum serum concentration (Cmax), area under the concentration-time curve (AUC), apparent serum clearance (CL/F), and apparent terminal volume of distribution (Vz/F) were determined by simple least-squares linear regression.
There were no significant relationships between either body weight or BSA and Cmax, AUC, Vz/F (corrected for weight), and clearance (P > 0.07; R2 < 0.06 for all comparisons). A significant positive association between Vz/F, uncorrected for weight, and either weight (P = 0.011; R2 = 0.121) or BSA (P = 0.022; R2 = 0.098) was observed. The interindividual coefficients of variation of CL/F and Vz/F values were only marginally reduced when the parameters were corrected for weight (31.3 versus 30.8% and 28.0 versus 26.0% respectively).
There is little or no linear association between either body weight or BSA and observed serum zidovudine concentrations following administration of 200 mg zidovudine in adult male patients who are within 20% of their ideal weight.
确定接受口服齐多夫定治疗的患者体重或体表面积(BSA)与血清齐多夫定药代动力学参数之间是否存在简单关系。
单剂量药代动力学研究。
53名无症状和有症状的HIV感染男性(CD4 +细胞计数<500×10⁶/l)参与了该研究。肾功能和血液学检查结果在正常范围内,所有肝功能检查结果最高为正常上限的三倍。患者接受200mg口服齐多夫定,并采集连续血样4小时(18例患者)或8小时(35例患者)。通过高效液相色谱法(12例患者)或放射免疫分析法(41例患者)测定血清齐多夫定浓度。通过非房室方法计算药代动力学参数。通过简单的最小二乘线性回归确定体重或BSA与最大血清浓度(Cmax)、浓度-时间曲线下面积(AUC)、表观血清清除率(CL/F)和表观终末分布容积(Vz/F)之间的关系。
体重或BSA与Cmax、AUC、Vz/F(校正体重后)和清除率之间均无显著关系(P>0.07;所有比较的R²<0.06)。观察到未校正体重的Vz/F与体重(P = 0.011;R² = 0.121)或BSA(P = 0.022;R² = 0.098)之间存在显著正相关。当参数校正体重后,CL/F和Vz/F值的个体间变异系数仅略有降低(分别为31.3%对30.8%和28.0%对26.0%)。
在体重在理想体重的20%以内的成年男性患者中,服用200mg齐多夫定后,体重或BSA与观察到的血清齐多夫定浓度之间几乎没有或不存在线性关联。